9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)

Phase 3

MERCK (MRK)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

MRKPhase 3$364.4B

9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Phase 3 Est. Readout

9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)• HPV Positive Oropharyngeal Squamous Cell Carcinoma700

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in HPV Positive Oropharyngeal Squamous Cell Carcinoma

View Full Landscape

Drug Information

Target Indication

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Clinical Trial

NCT04255849

Last updated: 8/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Vericiguat tabletPhase 3

Heart Failure

Pegylated interferon alfa-2b (SCH 54031)Phase 3

Hepatitis C, Chronic

ElbasvirPhase 3

Hepatitis C

V260Phase 3

Rotavirus Gastroenteritis

MK-8591APhase 3

HIV-1 Infection

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts